Siemens Healthineers Faces Twin Pressures: Government Austerity at Home and a Potential €6B Diagnostics Divestiture

Siemens Healthineers shares fall 21% YTD to €35.25 as German austerity plan hits hospitals, diagnostics sale looms, and US tariffs add pressure.

The shares of Siemens Healthineers have tumbled to a new 52-week low of €35.25, extending a year-to-date decline of roughly 21%. The selloff reflects a confluence of headwinds that range from domestic healthcare policy to transatlantic trade tensions, while behind the scenes the company is weighing a radical restructuring of its portfolio.

A €20 Billion Austerity Plan Hits Close to Home

Germany’s cabinet has approved the GKV Contribution Rate Stabilization Act, a sweeping cost-cutting measure championed by Health Minister Nina Warken that aims to save around €20 billion from the statutory health insurance system by 2027. More than 40% of those savings are slated to come from the hospital sector — a direct blow to Siemens Healthineers, whose imaging systems and laboratory diagnostics are heavily dependent on hospital procurement.

The timing could hardly be worse. Two-thirds of German hospitals are already operating in the red, and the Hessian hospital association has warned of an impending wave of insolvencies. The legislation is politically contentious: the SPD is pushing for targeted cuts on hospital operators rather than blanket reductions, while the CSU insists the federal government should fully cover healthcare costs for welfare recipients.

A Diagnostics Sale Could Reshape the Company

While the political drama unfolds in Berlin, the Healthineers management is pursuing a far more dramatic course of action. The company is exploring the sale of its struggling diagnostics division to private equity buyers, a deal that could fetch approximately €6 billion. The unit has been a drag on group performance — first-quarter revenues in diagnostics slipped by around 3%, with demand in China particularly weak.

A sale would serve two strategic purposes. First, it would remove a persistent operational drag. Second, and perhaps more critically, it would allow the company to make a serious dent in its €14 billion debt pile. The timing aligns with the broader corporate restructuring: Siemens AG has laid out a roadmap for a full separation of its remaining stake, with a shareholder vote on the direct spin-off scheduled for the February 2027 annual general meeting.

To prepare for life as an independent entity, Siemens Healthineers has secured a credit rating upgrade from Moody’s, which assigned an A3 rating with a stable outlook — a solid investment-grade credential for future capital market access.

Tariffs and Currency Headwinds Add to the Strain

The company’s financial outlook is also being squeezed by external forces. Management estimates that US tariffs will cost around €400 million in 2026, while adverse currency movements could add another €250 million to the bill. This vulnerability stems from the group’s geographic mismatch: roughly 40% of revenues are generated in the US, but the bulk of costs are denominated in euros.

Despite these pressures, Siemens Healthineers is sticking to its full-year guidance. The company targets revenue growth of 5% to 6% and adjusted earnings per share between €2.20 and €2.40. Over the medium term, management believes it can offset the tariff burden through price increases, cost discipline, and production relocation.

Radiopharmaceuticals Offer a Growth Hedge

Amid the near-term turbulence, the company is quietly building a position in radiopharmaceuticals. In April, it signed a clinical supply agreement with Radiopharm Theranostics, under which Siemens Healthineers will manufacture and distribute the PET imaging agent RAD101 through its US network of radiopharmacies. The agent, which targets brain metastases from solid tumors, has received FDA Fast Track designation for distinguishing tumor recurrence from treatment-related effects.

All Eyes on May 7

The next major catalyst arrives on May 7, when Siemens Healthineers reports second-quarter results. Investors will be looking for concrete updates on the diagnostics sale process, as well as evidence that the core business can absorb the margin pressure from tariffs and the China slowdown. The stock’s distance from its 200-day moving average has already stretched to nearly 19%, underscoring the depth of the bearish sentiment. Whether the company can deliver the strong second half needed to hit its targets — or whether further guidance cuts are in store — will define the narrative in the weeks ahead.